Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.57 is 42% above its 5-year average of -0.98, near the high end of its 5-year range (-1.54–-0.57).
27.98% above its 12-month average of -0.79.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.10.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 36 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.57
EARNINGS PER SHARE (EPS) AVG TTM
-0.79
EARNINGS PER SHARE (EPS) AVG 3Y
-0.77
EARNINGS PER SHARE (EPS) AVG 5Y
-0.98
EARNINGS PER SHARE (EPS) AVG 10Y
-1.02
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+27.98%
CURRENT VS 3Y AVG
+26.37%
CURRENT VS 5Y AVG
+41.91%
CURRENT VS 10Y AVG
+44.30%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
InflaRx N.V.
Market Cap
$232.72M
Earnings Per Share (EPS)
-0.57
TTM Avg
-0.79
3Y Avg
-0.77
5Y Avg
-0.98
Market Cap
$231.77M
Earnings Per Share (EPS)
-1.54
TTM Avg
-1.32
3Y Avg
-0.98
5Y Avg
-0.74
Market Cap
$231.37M
Earnings Per Share (EPS)
-0.22
TTM Avg
-1.13
3Y Avg
-1.09
5Y Avg
-1.70
Market Cap
$235.08M
Earnings Per Share (EPS)
3.28
TTM Avg
3.72
3Y Avg
4.14
5Y Avg
3.92
Market Cap
$235.66M
Earnings Per Share (EPS)
-0.11
TTM Avg
-0.18
3Y Avg
-0.30
5Y Avg
-0.87
Market Cap
$235.97M
Earnings Per Share (EPS)
-0.04
TTM Avg
0.58
3Y Avg
0.64
5Y Avg
0.70
Market Cap
$236.82M
Earnings Per Share (EPS)
-2.38
TTM Avg
-2.11
3Y Avg
-1.81
5Y Avg
-1.81
Market Cap
$237.57M
Earnings Per Share (EPS)
-0.39
TTM Avg
-0.86
3Y Avg
-1.43
5Y Avg
-1.56
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InflaRx N.V. (IFRX) | $232.72M | -0.57 | -0.79 | -0.77 | -0.98 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | -1.54 | -1.32 | -0.98 | -0.74 |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | -0.22 | -1.13 | -1.09 | -1.70 |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 3.28 | 3.72 | 4.14 | 3.92 |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | -0.11 | -0.18 | -0.30 | -0.87 |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | -0.04 | 0.58 | 0.64 | 0.70 |
| BioAge Labs Inc. (BIOA)vs › | $236.82M | -2.38 | -2.11 | -1.81 | -1.81 |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A | N/A | N/A | N/A |
| Invivyd, Inc. (IVVD)vs › | $237.57M | -0.39 | -0.86 | -1.43 | -1.56 |
| Biodesix, Inc. (BDSX)vs › | $227.60M | -3.17 | -5.64 | -13.77 | -18.37 |
Trailing EPS (TTM)
$-0.57
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.78 |
| 2024-12-31 | -0.81 |
| 2023-12-31 | -0.86 |
| 2022-12-31 | -0.65 |
| 2021-12-31 | -1.25 |
| 2020-12-31 | -1.54 |
| 2019-12-31 | -2.14 |
| 2018-12-31 | -1.36 |
| 2017-12-31 | -1.24 |
| 2016-12-31 | -0.40 |
| 2015-12-31 | -0.23 |
